Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valneva Starts COVID-19 Vaccine Production In Scotland

Initial Phase I/II Trial Data Expected In April

Executive Summary

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.

You may also be interested in...



Coronavirus Update: Another Vaccine Disappointment For GSK

After suffering a setback in its joint venture with Sanofi, GlaxoSmithKline has been dropped by another vaccine partner, Clover, as it looks for the best adjuvant for its COVID-19 candidate.

Coronavirus Notebook: EFPIA Attacks EU’s Vaccine Export Authorization Scheme, EMA Starts Rolling Review Of REGN-COV2 Antibody Combo

Médecins Sans Frontières has urged Johnson & Johnson to prioritize vaccine supplies to COVAX, the EMA has clarified the dosing interval for Pfizer/BioNTech’s Comirnaty, and the UK has ordered more vaccine from Valneva.

Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir

The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.

Topics

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel